EDGAR·FLOW

Invivyd, Inc. — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 48/100
What the filing says
Invivyd reported Q3 2026 PEMGARDA net product revenue of $15.4M (vs. $13.1M in Q3 2025, +18% YoY). VYD2311 LIBERTY Phase 3 trial showed superior safety vs. mRNA vaccine; FLINTLOCK Phase 2 initiated for Long COVID/vaccine injury; DECLARATION pivotal interim data expected imminently for Accelerated Approval BLA. Cash position: $126.4M as of Sept 30, 2026. R&D expenses surged to $18.7M (vs. $8.0M prior year); SG&A doubled to $30.3M (vs. $15.0M); net loss widened to $33.5M (vs. $10.5M). Marc Elia appointed CEO; measles antibody candidate VMS063 entering clinical development in 2027.
Why this rating

Revenue growth +18% modest for $51M company; core pipeline progress real but timeline slips and near-term cash burn elevated. PEMGARDA EUA terminates mid-2027—existential risk to current revenue.

View original filing on SEC.gov ↗ IVVD · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.